Bio News
Freenome’s blood-based colorectal cancer test, which Abbott exclusively markets, has received approval from the U.S. Food and Drug Administration (FDA) with 81.1% sensitivity. Abbott will pay Freenome $100 million as part of a commercialization agreement in 2025, and the test analyzes cell-free DNA (cfDNA) in blood. The test showed 90.4% specificity for advanced colorectal neoplasia and is expected to launch for average-risk individuals aged 45 and older.
Biobook Team
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
